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Introductory Paragraph 
Using the ImmunoChip custom genotyping array, we analysed 14,498 multiple sclerosis subjects and 24,091 
healthy controls for 161,311 autosomal variants and identified 135 potentially associated regions (p-value < 
1.0 x 10
-4
). In a replication phase, we combined these data with previous genome-wide association study 
(GWAS) data from an independent 14,802 multiple sclerosis subjects and 26,703 healthy controls.  In these 
80,094 individuals of European ancestry we identified 48 new susceptibility variants (p-value < 5.0 x 10
-8
); 
three found after conditioning on previously identified variants. Thus, there are now 110 established 
multiple sclerosis risk variants in 103 discrete loci outside of the Major Histocompatibility Complex.  With 
high resolution Bayesian fine-mapping, we identified five regions where one variant accounted for more 
than 50% of the posterior probability of association. This study enhances the catalogue of multiple sclerosis 
risk variants and illustrates the value of fine-mapping in the resolution of GWAS signals. 
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Main text 
Multiple sclerosis (OMIM 126200) is an inflammatory demyelinating disorder of the central nervous 
system that is a common cause of chronic neurological disability.
1,2
 It has its greatest prevalence amongst 
individuals of Northern European ancestry
3
 and is moderately heritable,
4
 with a sibling relative recurrence 
risk (λs) of ~ 6.3.
5
 Aside from the early success in demonstrating the important effects exerted by variants in 
the Human Leukocyte Antigen (HLA) genes from the Major Histocompatibility Complex (MHC),
6
 there 
was little progress in unravelling the genetic architecture underlying multiple sclerosis susceptibility prior to 
the advent of genome-wide association studies (GWAS). Over the last decade, our Consortium has 
performed several GWAS and meta-analyses in large cohorts,
7-10
 cumulatively identifying more than 50 
non-MHC susceptibility alleles. As in other complex diseases, available data suggest that many additional 
susceptibility alleles remain to be identified.
11
  
The striking overlap in the genetic architecture underlying susceptibility to autoimmune diseases
9,10,12,13
 
prompted the collaborative construction of the “ImmunoChip” (see Supplementary Note and 
Supplementary Figs. 1 and 2 for details of IMSGC nominated content),  an efficient genotyping platform 
designed to deeply interrogate 184 non-MHC loci with genome-wide significant associations to at least one 
autoimmune disease and provide lighter coverage of other genomic regions with suggestive evidence of 
association.
14
 Here, we report a large-scale effort that leverages the ImmunoChip to detect association with 
multiple sclerosis susceptibility and refine these associations via Bayesian fine-mapping. 
After stringent quality control (QC), we report genotypes on 28,487 individuals of European ancestry 
(14,498 multiple sclerosis subjects, 13,989 healthy controls) that are independent of previous GWAS efforts.  
We supplemented these data with 10,102 independent control subjects provided by the International 
Inflammatory Bowel Disease Genetics Consortium (IIBDGC)
15
 bringing the total to 38,589 individuals 
(14,498 multiple sclerosis subjects and 24,091 healthy controls). We performed variant level QC, population 
outlier identification, and subsequent case-control analysis in 11 country-organized strata. To account for 
within-stratum population stratification we used the first five principal components as covariates in the 
association analysis.  Per stratum odds ratios (OR) and respective standard errors (SE) were then combined 
with an inverse variance meta-analysis under a fixed effects model.  In total we tested 161,311 autosomal 
variants that passed QC in at least two of the 11 strata (Online Methods). A circos plot
16
 summarising the 
results from this discovery phase analysis is shown in Figure 1. 
We defined an a priori discovery threshold of p-value <1 x 10
-4
 and identified 135 primary statistically 
independent association signals; 67 in the designated fine-mapping regions and 68 in less densely covered 
regions selected for deep replication of earlier GWAS. Another 13 secondary and 2 tertiary statistically 
4 
independent signals were identified by forward stepwise logistic regression.  A total of 48 of the 150 
statistically independent association signals (Supplementary Table 1) reached a genome-wide significance 
p-value <5 x 10
-8
 at the discovery phase alone.  Next, we replicated our findings in 14,802 multiple sclerosis 
subjects and 26,703 healthy controls with available GWAS data imputed to the 1000 Genomes European 
phase I (a) panel (Online Methods). Finally, we performed a joint analysis of the discovery and replication 
phases. 
We identified 97 statistically independent SNPs meeting replication criteria (preplication < 0.05, pjoint < 5 x 
10
-8
, and pjoint < pdiscovery); 93 primary signals (Supplementary Figs. 3-95) and four secondary signals.  Of 
these, 48 are novel to multiple sclerosis (Table 1) and 49 correspond to previously identified multiple 
sclerosis effects (Table 2). An additional 11 independent SNPs showed suggestive evidence of association 
(pjoint < 1 x 10
-6
) (Supplementary Table 2). 
The strongest novel association, rs12087340 (pjoint = 1.1 x 10
-20
, OR = 1.21), lies between BCL10 (B-cell 
CLL / lymphoma 10) and DDAH1 (dimethylarginine dimethylaminohylaminohydrolase 1).  The protein 
encoded by BCL10 contains a caspase recruitment domain (CARD) and has been shown to activate NF-
kappaB.
17
 The latter is a signalling molecule that plays an important role in controlling gene expression in 
inflammation, immunity, cell proliferation, and apoptosis. It has been pursued as a potential therapeutic 
target for multiple sclerosis.
18
 BCL10 is also reported to interact with other CARD domain containing 
proteins including CARD11.
19
  We have also identified a novel association of rs1843938 (pjoint = 1.2 x 10
-10
, 
OR = 1.08), which is only 30 kb from CARD11. 
One novel SNP was found within an exon, rs2288904 (pjoint = 1.6 x 10
-11
, OR= 1.10); a missense variant in 
SLC44A2 (solute carrier family 44, member 2).  Notably, this variant is also reported as a monocyte-specifc 
cis-acting eQTL for the antisense transcript of the nearby ILF3 (interleukin enhancer binding factor 3).
20
  
This protein was first discovered to be a subunit of a nuclear factor found in activated T-cells, which is 
required for T-cell expression of IL2, an important molecule regulating many aspects of inflammation. 
Of the 49 previously identified effects,
9,10,21
 37 are in designated fine-mapping regions, and 23 of these 37 
signals were localized to a single gene based on genomic position (Supplementary Table 3).  Recognizing 
that proximity does not necessarily indicate functional importance, this emphasizes the utility of dense 
mapping in localizing signals from a genome-wide screen. The ImmunoChip analysis furthered the 
understanding of previously proposed secondary signals at three loci (Supplementary Note and 
Supplementary Tables 4-6); in particular we showed that the effects of two previously proposed 
independent associations at the IL2RA locus are driven by a single variant, rs2104286.
7,22
.  
5 
In an effort to define the functionally relevant variants underlying these associations, we further studied 
the regions surrounding the 97 associated SNPs using both a Bayesian and frequentist approach in 6,356 
multiple sclerosis subjects and 9,617 healthy controls from the UK (Online Methods).
23
  Based on 
imputation quality, fine-mapping was possible in 68 regions  (Supplementary Table 7): 66 of 93 primary 
(Fig. 2A) and two of four secondary. Eight of the 68 regions were fine-mapped to high resolution (Table 3, 
Fig. 2B and Supplementary Fig. 96).  One third of the variants identified in these eight regions were 
imputed, indicating reliance on imputation even with dense genotyping coverage.    
To assess whether functional annotation
24
 provides clues about the molecular mechanisms associated with 
genetic risk, we considered the relationship of variants to described coding and regulatory features in these 
eight regions.   Although we found no variants with missense or nonsense effects, there was a notable 
enrichment for variants with functional effects: one known to affect splicing,
25
 three known to correlate with 
RNA or serum protein levels
22,26,27
 and several in transcription-factor binding and DNase I hypersensitive 
sites.
28,29
  Four of the 18 variants in the fine-mapped regions are within conserved regions (GERP > 2).
30
 
This lack of functional annotation likely reflects the limited repertoire of reference expression and 
epigenomic profiles and suggests that the function of the variants may be cell-type or cell-state specific, as 
has been reported for many eQTLs in immune cell types.
20
   
To determine the Gene Ontology (GO) processes of the 97 associated variants, we used MetaCore from 
Thomson Reuters (Online Methods).  We found the majority of the 97 variants lie within 50 kb of genes 
having immunological function.  Of the 86 unique genes represented, 35 are linked to the GO immune 
system process (Table 1 and Table 2).  We do not see a substantial over- or under- representation of certain 
GO processes when comparing the novel and previously identified loci, but this may be a limitation of 
ImmunoChip targeting genomic loci enriched for immunologically active genes, with more subtle 
distinctions between them not adequately captured by broad annotations such as GO.  
Finally, we explored the overlap between our findings and those in autoimmune diseases with reported 
ImmunoChip analyses.  We calculated the percentage of multiple sclerosis signals (110 non-MHC, 
Supplementary Table 8) overlapping those of other autoimmune diseases by requiring an r
2
 ≥ 0.8 between 
the best variants reported in each study using SNAP.
31
 In total we find that ~22% of our signals overlap at 
least one other autoimmune disease. More specificially, ~9.1% overlap with inflammatory bowel disease 
(IBD) - ~7.3% with ulcerative colitis (UC), ~9.1% with Crohn’s disease (CD) - 15, ~9.1% with primary 
biliary cirrhosis (PBC),
32,33
 ~4.5% with celiac disease (CeD),
34
 ~4.5% with  rheumatoid arthritis (RhA),
35
 
~0.9% with psoriasis (PS),
36
 and ~2.7% with autoimmune thyroid disease (AITD).
37
 We report the same top 
variant seen in PBC for 7 loci. We also note that our best TYK2 variant (rs34536443)
38
 is also the most 
6 
associated variant for PBC, PS and RhA. Lastly, AITD, CeD, PBC, and RhA report variants with pairwise r
2 
≥ 0.8 to the multiple sclerosis variant near MMEL139 (Supplementary Table 8). 
In summary, we have identified 48 new multiple sclerosis susceptibility variants. These novel loci expand 
our understanding of the immune system processes implicated in multiple sclerosis. We estimate that the 
110 non-MHC established risk variants explain 20% of the sibling recurrence risk; 28% including the 
already identified MHC effects
9
 (Supplementary Note). Additionally, we have identified five regions 
where consistent high resolution fine-mapping implicated one variant which accounted for more than 50% 
of the posterior in previously identified regions of TNFSF14, IL2RA, TNFRSF1A, IL12A, and STAT4.  Our 
study further implicates NF-kappaB in multiple sclerosis pathobiology
18
, emphasizes the value of dense 
fine-mapping in large follow-up data sets, and exposes the urgent need for functional annotation in relevant 
tissues. Understanding the implicated networks and their relation to environmental risk factors will promote 
the development of rational therapies and may enable the development of preventive strategies.  
 
URLs 
ImmunoBase, http://www.immunobase.org/; eQTL browser, http://eqtl.uchicago.edu/; MetaCore, 
https://portal.genego.com/. 
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Figure Legends 
 
Figure 1. Discovery phase results. Primary association analysis of 161,311 autosomal variants in the 
discovery phase (based on 14,498 cases and 24,091 healthy controls). The outer most track shows the 
numbered autosomal chromosomes. The second track indicates the gene closest to the most associated SNP 
meeting all replication criteria.  Previously identified associations are indicated in grey.  The third track 
indicates the physical position of the 184 fine-mapping intervals (green).  The inner most track indicates –
log(p) (two-sided) for each SNP (scaled from 0-12 which truncates the signal in several regions, see 
Supplementary Table 1).  Additionally, contour lines are given at the a priori discovery(–log(p) = 4) and 
genome-wide significance (-log(p) = 7.3) thresholds.  Orange indicates -log(p) ≥ 4 and < 7.3, while red 
indicates –log(p) ≥ 7.3.  Details of the full discovery phase results can be found in ImmunoBase.  
 
 
Figure 2.  Bayesian fine-mapping within primary regions of association.  a) Summary of the extent of 
fine-mapping across 66 regions in 9,617 healthy controls from the UK, showing the the physical extent of,  
the number of variants, and the number of genes spanned by the posterior 90% and 50% credible sets.  b) 
Detail of fine-mapping in region of TNFSF14. Above the x-axis indicates the Bayes Factor summarizing 
evidence for association for the SNPs prior to conditioning (blue markers) while below the x-axis indicates 
the Bayes Factor after conditioning on the lead SNP (rs1077667). Mb=Megabases. 
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Table 1 48 Novel non-MHC susceptibility loci associated with multiple sclerosis at a genome-wide significance level 
    Discovery Replication Joint   
SNP Chr Positiona RA RAF P-value OR RAF P-value OR P-value OR Geneb Function 
rs3007421 1 6530189 A 0.12 9.6 x 10-7 1.12 0.13 8.8 x 10-5 1.10 4.7 x 10-10 1.11 PLEKHG5 intronic 
rs12087340 1 85746993 A 0.09 5.1 x 10-12 1.22 0.09 2.9 x 10-10 1.20 1.1 x 10-20 1.21 BCL10 intergenic 
rs11587876 1 85915183 A 0.79 8.4 x 10-8 1.12 0.81 2.9 x 10-3 1.06 4.4 x 10-9 1.09 DDAH1 intronic 
rs666930 1 120258970 G 0.53 7.5 x 10-8 1.09 0.53 1.3 x 10-5 1.07 6.0 x 10-12 1.08 PHGDH intronic 
rs2050568 1 157770241 G 0.53 1.3 x 10-6 1.08 0.54 2.3 x 10-5 1.07 1.5 x 10-10 1.08 FCRL1 intronic 
rs35967351 1 160711804 A 0.67 1.7 x 10-6 1.09 0.68 5.9 x 10-6 1.09 4.4 x 10-11 1.09 SLAMF7 intronic 
rs4665719 2 25017860 G 0.25 6.8 x 10-6 1.09 0.25 1.1 x 10-4 1.08 3.1 x 10-9 1.08 CENPO intronic 
rs842639 2 61095245 A 0.65 1.7 x 10-9 1.11 0.67 1.4 x 10-6 1.09 2.0 x 10-14 1.10 FLJ16341 ncRNA 
rs9967792 2 191974435 G 0.62 1.8 x 10-9 1.11 0.64 1.2 x 10-4 1.07 3.5 x 10-12 1.09 STAT4 intronic 
rs11719975 3 18785585 C 0.27 5.4 x 10-6 1.09 0.28 4.1 x 10-4 1.07 1.1 x 10-8 1.08  intergenic 
rs4679081 3 33013483 G 0.52 1.2 x 10-5 1.08 0.55 3.7 x 10-4 1.07 2.2 x 10-9 1.07 CCR4 intergenic 
rs9828629 3 71530346 G 0.62 5.5 x 10-6 1.08 0.64 8.5 x 10-6 1.08 1.9 x 10-10 1.08 FOXP1 intronic 
rs2726518 4 106173199 C 0.55 1.2 x 10-5 1.09 0.58 4.7 x 10-4 1.06 3.9 x 10-8 1.07 TET2 intronic 
rs756699 5 133446575 A 0.87 3.0 x 10-6 1.12 0.88 6.5 x 10-6 1.11 8.8 x 10-11 1.12 TCF7 intergenic 
nonec 5 141506564 C 0.61 6.0 x 10-5 1.07 0.62 1.5 x 10-5 1.08 3.6 x 10-9 1.07 NDFIP1 intronic 
rs4976646 5 176788570 G 0.34 1.0 x 10-12 1.13 0.36 5.0 x 10-7 1.10 4.4 x 10-18 1.12 RGS14 intronic 
rs17119 6 14719496 A 0.81 1.9 x 10-6 1.11 0.80 1.2 x 10-5 1.10 1.0 x 10-10 1.10  intergenic 
rs941816 6 36375304 G 0.18 4.5 x 10-9 1.13 0.20 8.3 x 10-5 1.08 3.9 x 10-12 1.11 PXT1 intronic 
rs1843938 7 3113034 A 0.44 2.2 x 10-6 1.08 0.44 1.1 x 10-5 1.08 1.2 x 10-10 1.08 CARD11 intergenic 
rs706015 7 27014988 C 0.18 1.3 x 10-9 1.14 0.18 9.9 x 10-3 1.06 1.1 x 10-9 1.10  intergenic 
rs917116 7 28172739 C 0.20 2.1 x 10-8 1.12 0.21 5.8 x 10-3 1.06 3.3 x 10-9 1.09 JAZF1 intronic 
rs60600003 7 37382465 C 0.10 2.5 x 10-8 1.16 0.10 4.2 x 10-7 1.14 6.0 x 10-14 1.15 ELMO1 intronic 
rs201847125d 7 50325567 G 0.70 2.9 x 10-8 1.11 0.70 6.7 x 10-5 1.09 1.2 x 10-11 1.10 IKZF1 intergenic 
rs2456449 8 128192981 G 0.36 2.2 x 10-8 1.10 0.37 3.8 x 10-3 1.05 1.8 x 10-9 1.08  intergenic 
rs793108 10 31415106 A 0.50 5.6 x 10-8 1.09 0.51 1.8 x 10-5 1.07 6.1 x 10-12 1.08  intergenic 
rs2688608 10 75658349 A 0.55 6.4 x 10-5 1.07 0.56 2.0 x 10-4 1.06 4.6 x 10-8 1.07 C10orf55 intergenic 
rs7120737 11 47702395 G 0.15 7.6 x 10-8 1.13 0.15 1.0 x 10-3 1.08 1.0 x 10-9 1.10 AGBL2 intronic 
rs694739 11 64097233 A 0.62 1.3 x 10-5 1.08 0.62 3.8 x 10-5 1.07 2.0 x 10-9 1.07 PRDX5 intergenic 
rs9736016 11 118724894 T 0.63 2.2 x 10-8 1.10 0.63 2.6 x 10-8 1.10 3.0 x 10-15 1.10 CXCR5 intergenic 
rs12296430 12 6503500 C 0.19 3.6 x 10-10 1.14 0.21 1.7 x 10-5 1.09 7.2 x 10-14 1.12 LTBR intergenic 
rs4772201 13 100086259 A 0.82 1.7 x 10-7 1.12 0.83 1.1 x 10-4 1.09 1.3 x 10-10 1.10 MIR548AN intergenic 
rs12148050 14 103263788 A 0.35 1.5 x 10-5 1.08 0.36 4.3 x 10-9 1.10 5.1 x 10-13 1.09 TRAF3 intronic 
rs59772922 15 79207466 A 0.83 4.0 x 10-6 1.11 0.83 5.4 x 10-4 1.08 1.2 x 10-8 1.09 CTSH intergenic 
rs8042861 15 90977333 A 0.44 9.8 x 10-7 1.08 0.45 3.4 x 10-4 1.06 2.2 x 10-9 1.07 IQGAP1 intronic 
rs6498184 16 11435990 G 0.81 2.1 x 10-10 1.15 0.82 6.5 x 10-9 1.14 7.4 x 10-18 1.15 RMI2 intergenic 
rs7204270* 16 30156963 G 0.50 9.3 x 10-8 1.09 0.49 3.7 x 10-5 1.08 1.6 x 10-11 1.09 MAPK3 intergenic 
rs1886700 16 68685905 A 0.14 8.8 x 10-6 1.11 0.14 3.2 x 10-4 1.08 1.3 x 10-8 1.10 CDH3 intronic 
rs12149527 16 79110596 A 0.47 1.7 x 10-6 1.08 0.47 4.3 x 10-6 1.08 3.3 x 10-11 1.08 WWOX intronic 
rs7196953 16 79649394 A 0.29 2.6 x 10-5 1.08 0.30 7.9 x 10-7 1.09 1.0 x 10-10 1.09 MAF intergenic 
rs12946510 17 37912377 A 0.47 8.5 x 10-6 1.08 0.48 8.0 x 10-5 1.07 2.9 x 10-9 1.07 IKZF3 intergenic 
rs4794058 17 45597098 A 0.50 1.6 x 10-5 1.07 0.52 3.5 x 10-10 1.11 1.0 x 10-13 1.09 NPEPPS intergenic 
rs2288904 19 10742170 G 0.77 9.6 x 10-10 1.14 0.78 5.4 x 10-4 1.07 1.6 x 10-11 1.10 SLC44A2 exonic 
rs1870071 19 16505106 G 0.29 5.7 x 10-10 1.12 0.30 4.6 x 10-7 1.09 2.0 x 10-15 1.10 EPS15L1 intronic 
rs17785991 20 48438761 A 0.35 6.4 x 10-7 1.09 0.34 5.9 x 10-3 1.05 4.2 x 10-8 1.07 SLC9A8 intronic 
rs2256814 20 62373983 A 0.19 8.3 x 10-7 1.11 0.21 6.4 x 10-4 1.08 3.5 x 10-9 1.09 SLC2A4RG intronic 
Secondary              
rs7769192e 6 137962655 G 0.55 1.3 x 10-5 1.08 0.54 5.1 x 10-5 1.07 3.3 x 10-9 1.08  intergenic 
rs533646f 11 118566746 G 0.68 3.6 x 10-7 1.10 0.68 3.9 x 10-5 1.08 7.6 x 10-11 1.09 TREH intergenic 
rs4780346g 16 11288806 A 0.23 6.8 x 10-6 1.09 0.25 1.5 x 10-5 1.09 4.4 x 10-10 1.09 CLEC16A intergenic 
All listed signals had a discovery P-value ≤ 1.0 x 10-4, a replication P-value ≤ 5.0 x 10-2, and a joint P-value ≤ 5.0 x 10-8 
All P-values are two-sided 
RA= Risk Allele, RAF = Risk Allele Frequency 
aPosition is based on human genome 19 and dbSNP 137. 
bNearest gene listed if within 50Kb.  Bold indicates Gene Ontology Immune System Process. 
A proxy SNP c(rs1036207, r2 = 0.99) and d(rs716719, r2=1.00) was used in replication.  
The P-value and OR values provided are after conditioning on ers67297943 (Known – see Table 2), frs9736016, and grs12927355 (Known – see Table 2). 
*Note primary was rs11865086 (P-value = 1.77 x 10-8) in Discovery but not available in Replication so the best proxy was used. 
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Table 2 49 Known non-MHC susceptibility loci associated with multiple sclerosis at a genome-wide significance level 
    Discovery Replication Joint   
SNP Chr Positiona RA RAF P-value OR RAF P-value OR P-value OR Geneb Function 
rs3748817 1 2525665 A 0.64 1.3 x 10-12 1.14 0.65 1.2 x 10-15 1.15 1.3 x 10-26 1.14 MMEL1 intronic 
rs41286801 1 92975464 A 0.14 7.9 x 10-16 1.20 0.16 2.1 x 10-12 1.17 1.4 x 10-26 1.19 EVI5 UTR3 
rs7552544* 1 101240893 A 0.56 3.7 x 10-6 1.08 0.43 3.3 x 10-12 1.12 1.9 x 10-16 1.10 VCAM1 intergenic 
rs6677309 1 117080166 A 0.88 1.5 x 10-28 1.34 0.88 4.1 x 10-16 1.24 5.4 x 10-42 1.29 CD58 intronic 
rs1359062 1 192541472 C 0.82 1.8 x 10-13 1.18 0.83 2.1 x 10-8 1.13 4.8 x 10-20 1.15 RGS1 intergenic 
rs55838263 1 200874728 A 0.71 1.4 x 10-9 1.12 0.71 3.9 x 10-11 1.13 4.0 x 10-19 1.13 C1orf106 intronic 
rs2163226 2 43361256 A 0.71 7.0 x 10-8 1.10 0.73 3.8 x 10-10 1.14 2.1 x 10-16 1.12  intergenic 
rs7595717 2 68587477 A 0.26 3.3 x 10-7 1.10 0.27 6.8 x 10-8 1.10 1.2 x 10-13 1.10 PLEK intergenic 
rs9989735 2 231115454 C 0.18 7.8 x 10-14 1.17 0.19 6.8 x 10-11 1.14 4.2 x 10-23 1.16 SP140 intronic 
rs2371108 3 27757018 A 0.38 2.1 x 10-6 1.08 0.39 5.8 x 10-11 1.12 1.5 x 10-15 1.10 EOMES downstream 
rs1813375 3 28078571 A 0.47 5.7 x 10-18 1.15 0.49 4.4 x 10-16 1.15 1.9 x 10-32 1.15  intergenic 
rs1131265 3 119222456 C 0.80 2.0 x 10-15 1.19 0.81 4.8 x 10-10 1.14 1.4 x 10-23 1.17 TIMMDC1 exonic 
rs1920296* 3 121543577 C 0.64 6.8 x 10-15 1.14 0.64 5.5 x 10-9 1.10 6.5 x 10-22 1.12 IQCB1 intronic 
rs2255214* 3 121770539 C 0.52 5.3 x 10-13 1.13 0.52 3.3 x 10-13 1.13 1.2 x 10-24 1.13 CD86 intergenic 
rs1014486 3 159691112 G 0.43 1.2 x 10-9 1.11 0.44 1.4 x 10-10 1.11 1.1 x 10-18 1.11 IL12A intergenic 
rs7665090 4 103551603 G 0.52 2.4 x 10-6 1.08 0.53 5.0 x 10-4 1.13 1.0 x 10-8 1.09 MANBA intergenic 
rs6881706 5 35879156 C 0.72 4.9 x 10-9 1.12 0.73 1.7 x 10-9 1.12 4.3 x 10-17 1.12 IL7R intergenic 
rs6880778 5 40399096 G 0.60 1.7 x 10-8 1.10 0.61 3.9 x 10-13 1.13 8.1 x 10-20 1.12  intergenic 
rs71624119 5 55440730 G 0.76 2.7 x 10-9 1.12 0.76 1.9 x 10-5 1.09 3.4 x 10-13 1.11 ANKRD55 intronic 
rs72928038 6 90976768 A 0.17 7.6 x 10-7 1.11 0.19 9.0 x 10-11 1.17 1.5 x 10-15 1.14 BACH2 intronic 
rs11154801 6 135739355 A 0.37 2.3 x 10-9 1.11 0.37 1.0 x 10-12 1.13 1.8 x 10-20 1.12 AHI1 intronic 
rs17066096 6 137452908 G 0.23 5.9 x 10-12 1.14 0.25 4.1 x 10-13 1.15 1.6 x 10-23 1.14 IL22RA2 intergenic 
rs67297943 6 138244816 A 0.78 4.8 x 10-8 1.12 0.80 2.5 x 10-6 1.11 5.5 x 10-13 1.11 TNFAIP3 intergenic 
rs212405 6 159470559 T 0.62 1.4 x 10-15 1.15 0.64 1.8 x 10-7 1.10 8.0 x 10-21 1.12 TAGAP intergenic 
rs1021156 8 79575804 A 0.24 5.6 x 10-10 1.12 0.26 2.1 x 10-8 1.11 8.5 x 10-17 1.11 ZC2HC1A intergenic 
rs4410871 8 128815029 G 0.72 2.0 x 10-9 1.12 0.72 3.4 x 10-8 1.11 4.3 x 10-16 1.11 MIR1204 intergenic 
rs759648 8 129158945 C 0.31 2.8 x 10-6 1.09 0.31 3.7 x 10-5 1.08 5.0 x 10-10 1.08 MIR1208 intergenic 
rs2104286 10 6099045 A 0.72 7.6 x 10-23 1.21 0.73 3.6 x 10-26 1.23 2.3 x 10-47 1.22 IL2RA intronic 
rs1782645 10 81048611 A 0.43 4.3 x 10-7 1.09 0.41 6.2 x 10-10 1.11 2.5 x 10-15 1.10 ZMIZ1 intronic 
rs7923837 10 94481917 G 0.61 4.6 x 10-9 1.11 0.62 2.0 x 10-9 1.11 4.3 x 10-17 1.11 HHEX intergenic 
rs34383631 11 60793330 A 0.40 5.7 x 10-10 1.11 0.39 4.5 x 10-15 1.15 3.7 x 10-23 1.13 CD6 intergenic 
rs1800693 12 6440009 G 0.40 6.9 x 10-16 1.14 0.41 1.0 x 10-13 1.14 6.7 x 10-28 1.14 TNFRSF1A intronic 
rs11052877 12 9905690 G 0.36 5.4 x 10-9 1.10 0.38 1.2 x 10-5 1.08 5.6 x 10-13 1.09 CD69 UTR3 
rs201202118c 12 58182062 A 0.67 7.4 x 10-13 1.14 0.67 1.6 x 10-10 1.12 9.0 x 10-22 1.13 TSFM intronic 
rs7132277 12 123593382 A 0.19 1.9 x 10-6 1.10 0.19 1.4 x 10-8 1.13 1.9 x 10-13 1.12 PITPNM2 intronic 
rs2236262 14 69261472 A 0.50 1.2 x 10-5 1.08 0.50 3.8 x 10-8 1.09 2.5 x 10-12 1.08 ZFP36L1 intronic 
rs74796499 14 88432328 C 0.95 8.5 x 10-11 1.31 0.95 4.5 x 10-11 1.33 2.4 x 10-20 1.32 GALC intronic 
rs12927355 16 11194771 G 0.68 8.2 x 10-27 1.21 0.69 4.3 x 10-21 1.18 6.4 x 10-46 1.20 CLEC16A intronic 
rs35929052 16 85994484 G 0.89 3.3 x 10-7 1.14 0.88 3.6 x 10-6 1.15 5.9 x 10-12 1.15 IRF8 intergenic 
rs4796791 17 40530763 A 0.36 1.8 x 10-8 1.10 0.36 1.2 x 10-13 1.14 3.7 x 10-20 1.12 STAT3 intronic 
rs8070345 17 57816757 A 0.45 5.4 x 10-16 1.14 0.46 1.9 x 10-9 1.10 2.2 x 10-23 1.12 VMP1 intronic 
rs1077667 19 6668972 G 0.79 3.5 x 10-13 1.16 0.79 8.4 x 10-13 1.16 1.7 x 10-24 1.16 TNFSF14 intronic 
rs34536443 19 10463118 C 0.95 1.2 x 10-8 1.28 0.96 2.9 x 10-7 1.30 1.8 x 10-14 1.29 TYK2 exonic 
rs11554159 19 18285944 G 0.73 2.6 x 10-13 1.15 0.74 1.4 x 10-12 1.15 1.9 x 10-24 1.15 IFI30 exonic 
rs8107548 19 49870643 G 0.25 2.0 x 10-6 1.09 0.26 2.5 x 10-10 1.13 5.7 x 10-15 1.11 DKKL1 intronic 
rs4810485 20 44747947 A 0.25 1.8 x 10-5 1.08 0.25 1.4 x 10-12 1.14 7.7 x 10-16 1.11 CD40 intronic 
rs2248359 20 52791518 G 0.60 9.8 x 10-5 1.07 0.62 8.2 x 10-11 1.12 2.0 x 10-13 1.09 CYP24A1 intergenic 
rs2283792 22 22131125 C 0.51 1.1 x 10-6 1.08 0.53 5.4 x 10-11 1.11 5.5 x 10-16 1.10 MAPK1 intronic 
Secondary              
rs523604d 11 118755738 A 0.53 2.5 x 10-7 1.09 0.54 4.0 x 10-9 1.11 6.2 x 10-15 1.10 CXCR5 intronic 
All listed signals had a discovery P-value ≤ 1.0 x 10-4, a replication P-value ≤ 5.0 x 10-2, and a joint P-value ≤ 5.0 x 10-8 
All P-values are two-sided 
RA = Risk Allele, RAF = Risk Allele Frequency 
aPosition is based on human genome 19 and dbSNP 137. 
bNearest gene listed if within 50Kb.  Bold indicates Gene Ontology Immune System Process.  
cA proxy SNP (rs10431552, r2 = 0.99) was used in replication. 
dThe P-value and OR values provided are after conditioning on rs9736016 and rs533646 (both Novel – see Table 1). 
* These three SNPs were not primary in the 2011 GWAS, two were secondary and the third was tertiary in that study. 
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Table 3 The 18 variants from the 8 regions with consistent high resolution fine-mapping 
Gene SNP Chr Positiona Posterior GERP Functional Annotationb 
TNFSF14 rs1077667 19 6668972 0.74 -3.89 
intronic, TFBS / DNase1 peak, correlates with serum levels of 
TNFSF14 
IL2RA rs2104286 10 6099045 0.93 -0.47 intronic, correlates with soluble IL-2RA levels 
TNFRSF1A rs1800693 12 6440009 0.69 2.53 intronic, causes splicing defect and truncated soluble TNFRSF1A 
 rs4149580c 12 6446990 0.10 2.06 intronic 
IL12A rs1014486 3 159691112 0.67 0.24 - 
CD6 rs34383631 11 60793330 0.20 1.66 - 
 rs4939490c 11 60793651 0.14 -0.53 - 
 rs4939491c 11 60793722 0.14 -0.37 - 
 rs4939489 11 60793648 0.10 3.25 - 
TNFAIP3 rs632574 6 137959118 0.27 -1.15 - 
 rs498549c 6 137984935 0.20 0.52 - 
 rs651973 6 137996134 0.17 2.41 downstream of RP11-95M15.1 lincRNA gene 
 rs536331 6 137993049 0.15 0.19 upstream of RP11-95M15.1 lincRNA gene 
CD58 rs6677309 1 117080166 0.21 -1.18 intronic, TFBS / DNase1 peak 
 rs35275493c 1 117095502 0.24 0.75 intronic (insertion) 
 rs10754324c 1 117093035 0.22 0.32 intronic 
 rs1335532 1 117100957 0.17 -1.32 intronic 
STAT4 rs78712823 2 191958581 0.59 -3.98 intronic 
All listed variants have posterior ≥ 0.1 in regions where ≤ 5 variants explain the top 50% of the posterior and the top SNP from the frequentist analysis lives 
in the 90% confidence interval, ordered by maximum posterior.     
Posterior denotes the posterior probability of any variant driving association.  GERP denotes Genomic Evolutionary Rate Profiling. 
aPosition is based on human genome 19 and dbSNP 137. 
bFunctional data from VEP, eQTL browser, Fairfax et al. (2012), pubmed searches, 1000G. Dash indicates intergenic with no additional annotation. 
Variants without annotation are intergenic and have no reported regulatory consequence.  
cImputed variant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
11 
Acknowledgements 
 
We thank participants, referring nurses, physicians, and funders - National Institutes of Health, Wellcome 
Trust, UK MS Society, UK Medical Research Council, US National MS Society, Cambridge NIHR BRC, 
DeNDRon, Bibbi and Niels Jensens Foundation, Swedish Brain Foundation, Swedish Research Council, 
Knut and Alice Wallenberg Foundation, Swedish Heart-Lung Foundation, Foundation for Strategic 
Research, Stockholm County Council, Karolinska Institutet, Institut National de la Santé et de la Recherche 
Médicale, Fondation d’Aide pour la Recherche sur la Sclérose En Plaques, Association Française contre les 
Myopathies, GIS-IBISA, German Ministry for Education and Research, German Competence Network MS, 
Deutsche Forschungsgemeinschaft, Munich Biotec Cluster M4, Fidelity Biosciences Research Initiative, 
Research Foundation Flanders, Research Fund KU Leuven, Belgian Charcot Foundation, Gemeinnützige 
Hertie Stiftung, University Zurich, Danish MS Society, Danish Council for Strategic Research, Academy of 
Finland, Sigrid Juselius Foundation, Helsinki University, Italian MS Foundation, Fondazione Cariplo, Italian 
Ministry of University and Research, CRT Foundation of Turin, Italian Ministry of Health, Italian Institute 
of Experimental Neurology, MS association of Oslo, Norwegian Research Council, South Eastern 
Norwegian Health Authorities, Australian National Health and Medical Research Council, Dutch MS 
Foundation, Kaiser Permanente. We acknowledge British 1958 Birth Cohort, UK National Blood Service, 
Vanderbilt University Medical Center’s BioVU DNA Resources Core, Centre de Ressources Biologiques du 
Réseau Français d’Etude Génétique de la Sclérose en Plaques, Norwegian Bone Marrow Registry, 
Norwegian MS Registry and Biobank, North American Research Committee on MS Registry, Brigham and 
Womens Hospital PhenoGenetic Project and DILGOM funded by the Academy of Finland. See 
Supplementary Note for details. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
12 
Author List and Affiliations 
Ashley H Beecham
1, 126, 
Nikolaos A Patsopoulos
2-6, 126
, Dionysia K Xifara
7
, Mary F Davis
8
, Anu 
Kemppinen
9
, Chris Cotsapas
10-12
, Tejas S Shahi
13
, Chris Spencer
7
, David Booth
14
, An Goris
15
, Annette 
Oturai
16
, Janna Saarela
17
, Bertrand Fontaine
18
, Bernhard Hemmer
19-21
, Claes Martin
22
, Frauke Zipp
23
, Sandra 
D'alfonso
24
, Filippo Martinelli-Boneschi
25, 26
, Bruce Taylor
27
, Hanne F Harbo
28, 29
, Ingrid Kockum
30
, Jan 
Hillert
30
, Tomas Olsson
30
, Maria Ban
9
, Jorge R Oksenberg
31
, Rogier Hintzen
32
, Lisa F Barcellos
33-35
, 
Wellcome Trust Case Control Consortium 2 (WTCCC2)
36
, International IBD Genetics Consortium 
(IIBDGC)
36
, Cristina Agliardi
37
, Lars Alfredsson
38
, Mehdi Alizadeh
39
, Carl Anderson
13
, Robert Andrews
13
, 
Helle Bach Søndergaard
16
, Amie Baker
9
, Gavin Band
7
, Sergio E Baranzini
31
, Nadia Barizzone
24
, Jeffrey 
Barrett
13
, Céline Bellenguez
7
, Laura Bergamaschi
24
, Luisa Bernardinelli
40
, Achim Berthele
19
, Viola 
Biberacher
19
, Thomas M C Binder
41
, Hannah Blackburn
13
, Izaura L Bomfim
30
, Paola Brambilla
25
, Simon 
Broadley
42
, Bruno Brochet
43
, Lou Brundin
30
, Dorothea Buck
19
, Helmut Butzkueven
44, 45
, Stacy J Caillier
31
, 
William Camu
46
, Wassila Carpentier
47
, Paola Cavalla
48, 49
, Elisabeth G Celius
28
, Irène Coman
50
, Giancarlo 
Comi
25, 26
, Lucia Corrado
24
, Leentje Cosemans
15
, Isabelle Cournu-Rebeix
18
, Bruce A C Cree
31
, Daniele 
Cusi
51
, Vincent Damotte
18
, Gilles Defer
52
, Silvia R Delgado
53
, Panos Deloukas
13
, Alessia di Sapio
54
, 
Alexander T Dilthey
7
, Peter Donnelly
7
, Bénédicte Dubois
15
, Martin Duddy
55
, Sarah Edkins
13
, Irina 
Elovaara
56
, Federica Esposito
25, 26
, Nikos Evangelou
57
, Barnaby Fiddes
9
, Judith Field
58
, Andre Franke
59
, 
Colin Freeman
7
, Irene Y Frohlich
2
, Daniela Galimberti
60, 61
, Christian Gieger
62
, Pierre-Antoine Gourraud
31
, 
Christiane Graetz
23
, Andrew Graham
63
, Verena Grummel
19
, Clara Guaschino
25, 26
, Athena Hadjixenofontos
1
, 
Hakon Hakonarson
64, 65
, Christopher Halfpenny
66
, Gillian Hall
67
, Per Hall
68
, Anders Hamsten
69
, James 
Harley
70
, Timothy Harrower
71
, Clive Hawkins
72
, Garrett Hellenthal
73
, Charles Hillier
74
, Jeremy Hobart
75
, 
Muni Hoshi
19
, Sarah E Hunt
13
, Maja Jagodic
30, Ilijas Jelčić76, 77, Angela Jochim19, Brian Kendall78, Allan 
Kermode
79, 80
, Trevor Kilpatrick
81
, Keijo Koivisto
82
, Ioanna Konidari
1
, Thomas Korn
19
, Helena Kronsbein
19
, 
Cordelia Langford
13
, Malin Larsson
83
, Mark Lathrop
84-86
, Christine Lebrun-Frenay
87
, Jeannette Lechner-
Scott
88
, Michelle H Lee
2
, Maurizio A Leone
89
, Virpi Leppä
17
, Giuseppe Liberatore
25, 26
, Benedicte A Lie
29, 
90
, Christina M Lill
23, 91
, Magdalena Lindén
30
, Jenny Link
30
, Felix Luessi
23
, Jan Lycke
92
, Fabio Macciardi
93, 
94
, Satu Männistö
95
, Clara P Manrique
1
, Roland Martin
76, 77
, Vittorio Martinelli
26
, Deborah Mason
96
, Gordon 
Mazibrada
97
, Cristin McCabe
10
, Inger-Lise Mero
28, 29, 90
, Julia Mescheriakova
32
, Loukas Moutsianas
7
, Kjell-
Morten Myhr
98
, Guy Nagels
99
, Richard Nicholas
100
, Petra Nilsson
101
, Fredrik Piehl
30
, Matti Pirinen
7
, Siân E 
Price
102
, Hong Quach
33
, Mauri Reunanen
103, 104
, Wim Robberecht
105-107
, Neil P Robertson
108
, Mariaemma 
Rodegher
26
, David Rog
109
, Marco Salvetti
110
, Nathalie C Schnetz-Boutaud
8
, Finn Sellebjerg
16
, Rebecca C 
Selter
19
, Catherine Schaefer
35
, Sandip Shaunak
111
, Ling Shen
35
, Simon Shields
112
, Volker Siffrin
23
, Mark 
Slee
113
, Per Soelberg Sorensen
16
, Melissa Sorosina
25
, Mireia Sospedra
76, 77
, Anne Spurkland
114
, Amy 
Strange
7
, Emilie Sundqvist
30
, Vincent Thijs
105-107
, John Thorpe
115
, Anna Ticca
116
, Pentti Tienari
117
, Cornelia 
van Duijn
118
, Elizabeth M Visser
119
, Steve Vucic
14
, Helga Westerlind
30
, James S Wiley
58
, Alastair 
Wilkins
120
, James F Wilson
121
, Juliane Winkelmann
19, 20, 122, 123
, John Zajicek
75
, Eva Zindler
23
, Jonathan L 
Haines
8
, Margaret A Pericak-Vance
1
, Adrian J Ivinson
124
, Graeme Stewart
14
, David Hafler
10, 11, 125
, Stephen 
L Hauser
31
, Alastair Compston
9
, Gil McVean
7
, Philip De Jager
2, 5, 10, 126
, Stephen Sawcer
9, 126
, Jacob L 
McCauley
1, 126
 
 
 
13 
 
 
1. John P.  Hussman Institute for Human Genomics, University of Miami, Miller School of Medicine, 
Miami, Florida, USA. 
2. Department of Neurology, Program in Translational NeuroPsychiatric Genomics, Institute for the 
Neurosciences, Brigham & Women's Hospital, Boston, Massachusetts, USA. 
3. Department of Psychiatry, Program in Translational NeuroPsychiatric Genomics, Institute for the 
Neurosciences, Brigham & Women's Hospital, Boston, Massachusetts, USA. 
4. Department of Medicine, Division of Genetics, Brigham & Women's Hospital, Harvard Medical 
School, Boston, Massachusetts, USA. 
5. Harvard Medical School, Boston, Massachusetts, USA. 
6. Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, Massachusetts, 
USA. 
7. The Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK. 
8. Center for Human Genetics Research, Vanderbilt University Medical Center, Nashville, Tennessee, 
USA. 
9. Department of Clinical Neurosciences, Addenbrooke's Hospital, University of Cambridge, 
Cambridge, UK. 
10. Program in Medical and Population Genetics, Broad Institute of Harvard University and MIT, 
Cambridge, Massachusetts, USA. 
11. Department of Neurology, Yale University School of Medicine, New Haven, Connecticut, USA. 
12. Department of Genetics, Yale University School of Medicine, New Haven, Connecticut, USA. 
13. Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, UK. 
14. Westmead Millennium Institute, University of Sydney, New South Wales, Australia. 
15. Section of Experimental Neurology, Laboratory for Neuroimmunology, KU Leuven, Leuven, 
Belgium. 
16. Department of Neurology, Danish Multiple Sclerosis Center, Copenhagen University Hospital, 
Copenhagen, Denmark. 
17. Institute for Molecular Medicine Finland, University of Helsinki, Helsinki, Finland. 
18. Département de Neurologie, INSERM UMR S 975 CRICM, UPMC, Pitié-Salpêtrière, Paris, France. 
19. Department of Neurology, Klinikum rechts der Isar, Technische Universität München, Munich, 
Germany. 
20. Munich Cluster for Systems Neurology (SyNergy), Munich, Germany. 
21. German Competence Network Multiple Sclerosis (KKNMS), Munich, Germany. 
22. Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet, Stockholm, Sweden. 
23. Focus Program Translational Neuroscience (FTN), Rhine Main Neuroscience Network (rmn2), 
Johannes Gutenberg University-Medical Center, Mainz, Germany. 
24. Department of Health Sciences and Interdisciplinary Research Center of Autoimmune Diseases 
(IRCAD), University of Eastern Piedmont, Novara, Italy. 
25. Laboratory of Genetics of Neurological complex disorders, Institute of Experimental Neurology 
(INSPE), Division of Neuroscience, San Raffaele Scientific Institute, Milan, Italy. 
26. Department of Neurology, Institute of Experimental Neurology (INSPE), Division of Neuroscience, 
San Raffaele Scientific Institute, Milan, Italy. 
27. Menzies Research Institute Tasmania, University of Tasmania, Tasmania, Australia. 
28. Department of Neurology, Oslo University Hospital, Ullevål, Oslo, Norway. 
29. University of Oslo, Oslo, Norway. 
30. Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden. 
14 
31. Department of Neurology, University of California at San Francisco, Sandler Neurosciences Center, 
San Francisco, California, USA. 
32. Department of Neurology, MS Center ErasMS, Erasmus MC, Rotterdam, The Netherlands. 
33. Division of Epidemiology, Genetic Epidemiology and Genomics Laboratory, School of Public 
Health, University of California, Berkeley, California, USA. 
34. California Institute for Quantitative Biosciences (QB3), University of California, Berkeley, 
California, USA. 
35. Kaiser Permanente Division of Research, Oakland, California, USA. 
36. Lists of authors and members appear in the Supplementary Note. 
37. Laboratory of Molecular Medicine and Biotechnology, Don C. Gnocchi Foundation ONLUS, IRCCS 
S. Maria Nascente, Milan, Italy. 
38. Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden. 
39. Université Rennes 1, Rennes, France. 
40. Medical Research Council Biostatistics Unit, Cambridge, UK. 
41. Department of Transfusion Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, 
Germany. 
42. School of Medicine, Griffith University, Gold Coast, Queensland, Australia. 
43. CHU Pellegrin, Université Bordeaux 2, Bordeaux, France. 
44. University of Melbourne, Victoria, Melbourne, Australia. 
45. Department of Neurology, Box Hill Hospital, Monash University, Victoria, Australia. 
46. Service de Neurologie, CHRU Montpellier, Montpellier, France. 
47. Plateforme Post-Génomique P3S, UPMC-INSERM, Paris, France. 
48. Department of Neuroscience, MS Center, Azienda ospedaliera Città della Salute e della Scienza di 
Torino, Turin, Italy. 
49. University of Turin, Turin, Italy. 
50. Service de Neurologie, Hôpital Avicenne, Bobigny, France. 
51. Department of Health Sciences, San Paolo Hospital and Filarete Foundation, University of Milan, 
Milan, Italy. 
52. Service de Neurologie, CHU de Caen and INSERM U 919-GIP Cyceron, Caen, France. 
53. Department of Neurology, Multiple Sclerosis Division, Miller School of Medicine, University of 
Miami, Miami, Florida, USA. 
54. Neurologia 2 - CRESM, AOU San Luigi, Orbassano, Turin, Italy. 
55. Department of Neurology, Royal Victoria Infirmary, Newcastle upon Tyne, UK. 
56. Department of Neurology, University of Tampere, Medical School, Tampere, Finland. 
57. Division of Clinical Neurology, Nottingham University Hospital, Nottingham, UK. 
58. Florey Institute of Neuroscience and Mental Health, University of Melbourne, Victoria, Australia. 
59. Institute of Clinical Molecular Biology, Christian-Albrechts-University of Kiel, Kiel, Germany. 
60. Department of Pathophysiology and Transplantation, Neurology Unit, University of Milan, Milan, 
Italy. 
61. Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milan, Italy. 
62. KORAgen, Helmholtz Zentrum München, German Research Center for Environmental Health 
(GmbH), Institute of Genetic Epidemiology, Neuherberg, Germany. 
63. Department of Clinical Neurology, The Ipswich Hospital NHS Trust, Ipswich, UK. 
64. Center for Applied Genomics, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, 
USA. 
65. Department of Pediatrics, The Perelman School of Medicine, University of Pennsylvania, 
Philadelphia, Pennsylvania, USA. 
66. Wellcome Trust Clinical Research Facility, Southampton General Hospital, Southampton, UK. 
67. Department of Neurology, Aberdeen Royal Infirmary, Aberdeen, UK. 
68. Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden. 
15 
69. Department of Medicine at Karolinska University Hospital Solna, Atherosclerosis Research Unit, 
Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden. 
70. Department of Neurology, Hull Royal Infirmary, Hull, UK. 
71. Department of Neurology, Royal Devon and Exeter Foundaton Trust Hospital, Exeter, Devon, UK. 
72. Keele University Medical School, University Hospital of North Staffordshire, Stoke-on-Trent, UK. 
73. UCL Genetics Institute (UGI), University College London, London, UK. 
74. Department of Neurology, Poole General Hospital, Poole, UK. 
75. Plymouth University Peninsula Schools of Medicine and Dentistry, Plymouth, UK. 
76. Institute for Neuroimmunology and Clinical MS Research (inims), Center for Molecular 
Neurobiology (ZMNH), University Medical Center Hamburg-Eppendorf, Hamburg, Germany. 
77. Department of Neuroimmunology and MS Research, Neurology Clinic, University Hospital Zürich, 
Zürich, Switzerland. 
78. Department of Neurology, Division of Clinical Neurology, Leicester Royal Infirmary, Leicester, UK. 
79. Australian Neuromuscular Research Institute, University of Western Australia, Western Australia, 
Australia. 
80. Murdoch University, Western Australia, Australia. 
81. Melbourne Neuroscience Institute, University of Melbourne, Victoria, Australia. 
82. Department of Neurology, Seinäjoki Central Hospital, Seinäjoki, Finland. 
83. IFM Bioinformatics, Linköping University, Linköping, Sweden. 
84. Fondation Jean Dausset - Centre d'Etude du Polymorphisme Humain, Paris, France. 
85. Commissariat à l′Energie Atomique, Institut Genomique, Centre National de Génotypage, Evry, 
France. 
86. McGill University and Genome Quebec Innovation Center, Montreal, Canada. 
87. Service de Neurologie, Hôpital Pasteur, CHRU Nice, France. 
88. Hunter Medical Research Institute, University of Newcastle, New South Wales, Australia. 
89. Department of Neurology, Ospedale Maggiore, Novara, Italy. 
90. Department of Medical Genetics, Oslo University Hospital, Ullevål, Oslo, Norway. 
91. Department of Vertebrate Genomics, Neuropsychiatric Genetics Group, Max Planck Institute for 
Molecular Genetics, Berlin, Germany. 
92. Department of Clinical Neurosciences and Rehabilitation, Institute of Neuroscience and Physiology, 
Sahlgrenska Academy, Göteborgs Universitet, Göteborg, Sweden. 
93. Department of Psychiatry and Human Behavior, School of Medicine, University of California, 
Irvine, California, USA. 
94. Department of Pharmacological and Biomolecular Sciences, University of Milan, Milan, Italy. 
95. Department of Chronic Disease Prevention, National Institute for Health and Welfare, Helsinki, 
Finland. 
96. Canterbury District Health Board, Christchurch, New Zealand. 
97. Department of Neurology, Queen Elizabeth Medical Centre, Edgbaston, Birmingham, UK. 
98. Department of Neurology, The Norwegian Multiple Sclerosis Registry and Biobank, Haukeland 
University Hospital, Bergen, Norway. 
99. National Multiple Sclerosis Center Melsbroek, Melsbroek, Belgium. 
100. Neurology Department, Charing Cross Hospital, London, UK. 
101. Department of Clinical Sciences, Lund University, Lund, Sweden. 
102. Department of Neurology, Royal Hallamshire Hospital, Sheffield, UK. 
103. Department of Neurology, University of Oulu, Oulu, Finland. 
104. Department of Neurology, University Hospital of Oulu, Oulu, Finland. 
105. Laboratory of Neurobiology, Vesalius Research Center, Leuven, Belgium. 
106. Experimental Neurology, Leuven Research Institute for Neurodegenerative Diseases (LIND), 
University of Leuven (KU Leuven), Leuven, Belgium. 
107. Department of Neurology, University Hospitals Leuven, Leuven, Belgium. 
16 
108. Institute of Psychological Medicine and Clinical Neuroscience, Cardiff University, University 
Hospital of Wales, Cardiff, UK. 
109. Department of Neurology, Greater Manchester Neurosciences Centre, Salford Royal NHS 
Foundation Trust, Salford, UK. 
110. Department of Neuroscience, Centre for Experimental Neurological Therapies, Mental Health and 
Sensory Organs, Sapienza Università di Roma, Rome, Italy. 
111. Department of Neurology, Royal Preston Hospital, Preston, UK. 
112. Department of Neurology, Norfolk and Norwich Hospital, Norwich, UK. 
113. Department of Neurology, Flinders University, Adelaide, South Australia, Australia. 
114. Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway. 
115. Department of Neurology, Peterborough City Hospital, Peterborough, UK. 
116. Neurology and Stroke Unit, San Francesco Hospital, Nuoro, Italy. 
117. Department of Neurology, Helsinki University Central Hospital and Molecular Neurology 
Programme, Biomedicum, University of Helsinki, Helsinki, Finland. 
118. Department of Epidemiology, Erasmus MC, Rotterdam, The Netherlands. 
119. Division of Applied Health Sciences, University of Aberdeen, Foresterhill, Aberdeen, UK. 
120. Institute of Clinical Neurosciences, University of Bristol, Frenchay Hospital, Bristol, UK. 
121. Centre for Population Health Sciences, University of Edinburgh, Edinburgh, UK. 
122. Institut für Humangenetik, Technische Universität München, Munich, Germany. 
123. Institut für Humangenetik, Helmholtz Zentrum München, Munich, Germany. 
124. Harvard NeuroDiscovery Center, Harvard Medical School, Boston, Massachusetts, USA. 
125. Department of Immunobiology, Yale University School of Medicine, New Haven, Connecticut, 
USA. 
126. These authors contributed equally to this work. 
 
Corresponding author: 
Jacob L. McCauley 
jmccauley@med.miami.edu 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
17 
 
 
 
 
Author Contributions 
 
M.F.D., D. Booth, A.O., J.S., B. Fontaine, B.H., C. Martin, F.Z., S.D.'A., F.M.-B., B.T., H.F.H., I. Kockum, 
J. Hillert, T.O., J.R.O., R.H., L.F.B., C. Agliardi, L.A., L. Bernardinelli, V.B., S.B., B.B., L. Brundin, D. 
Buck, H. Butzkeuven, W. Camu, P.C., E.G.C., I.C., G.C., I.C.-R., B.A.C.C., G.D., S.R.D., A.D.S., B.D., 
M.D., I.E., F.E., N.E., J.F., A.F., I.Y.F., D.G., C. Graetz, A. Graham, C. Guaschino, C. Halfpenny, G. Hall, 
J. Harley, T.H., C. Hawkins, C. Hillier, J. Hobart, M.H., I.J., A.J., B.K., A. Kermode, T. Kilpatrick, K.K., T. 
Korn, H.K., C.L.-F., J.L.-S, M.H.L., M.A.L., G.L., B.A.L., C.M.L., F.L., J. Lycke, S.M., C.P.M., R.M., 
V.M., D.M., G. Mazibrada, J.M., K.M., G.N., R.N., P.N., F.P., S.E.P., H.Q., M. Reunanen, W.R., N.P.R., M. 
Rodegher, D.R., M. Salvetti, F.S., R.C.S., C. Schaefer, S. Shaunak, L.S., S. Shields, V.S., M. Slee, P.S.S., 
M. Sospedra, A. Spurkland, V.T., J.T., A.T., P.T., C.V.D., E.M.V., S.V., J.S.W., A.W., J.F.W., J.Z., E.Z., 
J.L.H., M.A.P.-V., G.S., D.H., S.L.H., A.C., P.D.J., S.J.S. and J.L.M. were involved with case ascertainment 
and phenotyping . A. Kemppinen, D. Booth, A. Goris, A.O., B. Fontaine, S.D.'A., F.M.-B., H.F.H., I. 
Kockum, M.B., J.R.O., L.F.B., IIBDGC, H.B.S., A. Baker, N.B., L. Bergamaschi, I.L.B., P.B., D. Buck, 
S.J.C., L. Corrado, L. Cosemans, I.C.-R., V.D., J.F., A.F., V.G., I.J., I. Konidari, V.L., C.M.L., M. Lindén, J. 
Link, C. McCabe, I.M., H.Q., M. Sorosina, E.S., H.W., P.D.J., S.J.S. and J.L.M. processed the DNA. A. 
Kemppinen, A.O., B. Fontaine, M.B., R.H., L.F.B., WTCCC2, IIBDGC, R.A., H.B.S., N.B., T.M.C.B., H. 
Blackburn, P.B., W. Carpentier, L. Corrado, I.C.-R., D.C., V.D., P. Deloukas, S.E., A.F., H.H., P.H., A. 
Hamsten, S.E.H., I.J., I. Konidari, C.L., M. Larsson, M. Lathrop, F.M., I.M., J.M., H.Q., F.S., M. Sorosina, 
C.V.D., J.W., D.H., P.D.J., S.J.S. and J.L.M. conducted and supervised the genotyping of samples. A.H.B., 
N.A.P., D.K.X., M.F.D., A. Kemppinen, C.C., T.S.S., C. Spencer, M.B., IIBDGC, C. Anderson, S.E.B., 
A.T.D., P. Donnelly, B. Fiddes, P.G., G. Hellenthal, S.E.H., L.M., M.P., N.C.S.-B., J.L.H., M.A.P.-V., G. 
McVean, P.D.J., S.J.S. and J.L.M. performed the statistical analysis . A.H.B., N.A.P., D.K.X., M.F.D., A. 
Kemppinen, C.C., T.S.S., C. Spencer, D. Booth, A. Goris, A.O., J.S., B. Fontaine, B.H., F.Z., S.D.'A., F.M.-
B., H.F.H., I. Kockum, M.B., R.H., L.F.B., C. Agliardi, M.A., C. Anderson, R.A., H.B.S., A. Baker, G.B., 
N.B., J.B., C.B., L. Bernardinelli, A. Berthele, V.B., T.M.C.B., H. Blackburn, I.L.B., B.B., D. Buck, S.J.C., 
W. Camu, P.C., E.G.C., I.C., G.C., L. Corrado, L. Cosemans, I.C.-R., B.A.C.C., D.C., G.D., S.R.D., P. 
Deloukas, A.D.S., A.T.D., P. Donnelly, B.D., M.D., S.E., F.E., N.E., B. Fiddes, J.F., A.F., C.F., D.G., C. 
Gieger, C. Graetz, A. Graham, V.G., C. Guaschino, A. Hadjixenofontos, H.H., C. Halfpenny, P.H., G. Hall, 
A. Hamsten, J. Harley, T.H., C. Hawkins, G. Hellenthal, C. Hillier, J. Hobart, M.H., S.E.H., I.J., A.J., B.K., 
I. Konidari, H.K., C.L., M. Larsson, M. Lathrop, C.L.-F., M.A.L., V.L., G.L., B.A.L., C.M.L., F.M., C.P.M., 
R.M., V.M., G. Mazibrada, C. McCabe, I.M., L.M., K.M., R.N., M.P., S.E.P., H.Q., N.P.R., M. Rodegher, 
D.R., M. Salvetti, N.C.S.-B., R.C.S., C. Schaefer, S. Shaunak, L.S., S. Shields, M. Sospedra, A. Strange, 
J.T., A.T., E.M.V., A.W., J.F.W., J.W., J.Z., J.L.H., A.J.I., G. McVean, P.D.J., S.J.S. and  J.L.M. collected 
and managed the project data. A.H.B., N.A.P., M.F.D., A. Kemppinen, C.C., T.S.S., C. Spencer, J.S., B.H., 
F.Z., S.D.'A., F.M.-B., H.F.H., J. Hillert, T.O., M.B., J.R.O., R.H., L.F.B., L.A., C. Anderson, G.B., J.B., 
C.B., A. Berthele, E.G.C., G.C., P. Donnelly, F.E., C.F., C. Gieger, C. Graetz, G. Hellenthal, M.J., T. Korn, 
M.A.L., R.M., M.P., M. Sospedra, A. Spurkland, A. Strange, J.W., J.L.H., M.A.P.-V., A.J.I., G.S., D.H., 
S.L.H., A.C., G. McVean, P.D.J., S.J.S. and J.L.M. contributed to the study concept and design. A.H.B., 
N.A.P., D.K.X., G. McVean, P.D.J., S.J.S. and  J.L.M. prepared the manuscript. All authors reviewed the 
final manuscript. 
 
 
The authors have no competing financial interests 
 
 
18 
 
 
 
 
Online Methods 
 
ImmunoChip data (discovery set). 
Details of case ascertainment, processing and genotyping for the discovery phase are provided in the 
Supplementary Note (Supplementary Table 9). Genotype calling for all samples was performed using 
Opticall.
40
  Samples that performed poorly or were determined to be related were removed (Supplementary 
Table 10).  The data were organized in 11 country level strata:  ANZ (Australia + New Zealand), Belgium, 
Denmark, Finland, France, Germany, Italy, Norway, Sweden, United Kingdom (UK), and the United States 
of America (USA).  SNP level quality control (Supplementary Table 11) and population outlier 
identification using principal components analysis (Supplementary Fig. 97) were done in each stratum 
separately.  
Discovery set analysis. 
We applied logistic regression, assuming a per-allelic genetic model per data set, including the first five 
principal components as covariates to correct for population stratification (Supplementary Table 12 lists 
the per data set genomic inflation factors, λ).  We then performed an inverse-variance meta-analysis of the 
11 strata, under a fixed effects model, as implemented in PLINK.
41
 To be more conservative and account for 
any residual inflation in the test statistic, we applied the genomic control equivalent to the per-SNP standard 
error in each stratum. Specifically, we corrected the SNP standard errors by multiplying them with the 
square root of the raw genomic inflation factor λ, per data set, if the λ was >1. 
Within the designated fine-mapping intervals, we applied a forward stepwise logistic regression to identify 
statistically independent effects.  The primary SNP in each interval was included as a covariate, and the 
association analysis was repeated for the remaining SNPs.  This process was repeated until no SNPs reached 
the minimum level of significance (p-value <1 x 10
-4
).  Outside of the designated fine-mapping intervals, all 
SNPs having a p-value <1 x 10
-4
 were identified and grouped into sets based on a physical distance of less 
than 2Mb and a similar stepwise regression model was applied. Any SNPs to enter the model with p-value 
<1 x 10
-4
 after conditioning were considered statistically independent primary signals.   
In addition, because of the close physical proximity between some fine-mapping intervals and SNP sets, 
independence was tested for all identified signals within 2Mb of one another.  The and cluster plots 
(Supplementary Fig. 98) of all independent SNPs were examined, and the SNP was excluded if 
unsatisfactory.  If any SNP was excluded, the forward stepwise logistic regression within that fine-mapping 
19 
interval or SNP set was repeated after removal of the SNP.  During this process, 17 additional SNPs were 
excluded based on cluster or forest plot review.  
 
  
Replication Set.   
The replication phase included GWAS data organized into 15 strata.  Within each stratum, poorly 
performing samples (call rate < 95%, gender discordance, excess heterozygosity) and poorly performing 
SNPs (Hardy-Weinberg equilibrium (HWE) p-value <1 x 10
-6
, minor allele frequency (MAF) < 1%, call rate 
< 95%) were removed.  Principal components analysis was performed to identify population outliers per 
stratum, and the genomic control inflation factor was < 1.1 for each.  The data included in the final 
discovery and replication analyses are summarized in Supplementary Table 13 and Supplementary Table 
14. All the samples used in the replication set were unrelated to those in the discovery set; verified by 
identity-by-descent analysis. 
We attempted replication of all non-MHC independent signals that reached a discovery p-value of <1 x 10
-
4
 in a meta-analysis set of GWAS. Each data set was imputed to the 1000 Genomes European phase I (a) 
panel using BEAGLE
42
 to maximize the overlap between the Immunochip SNP content and the GWAS data. 
Post-imputation genotypic probabilities were used in a logistic regression model, per stratum, to estimate 
SNP effect sizes and p-values. By using the post-imputation genotypic probabilities, we penalized SNPs that 
didn’t have good imputation quality, thus ensuring a conservative analysis. Furthermore, we accounted for 
population stratification in each data set by including the first five principal components in the logistic 
model. We then meta-analysed the effect size and respective standard errors of the 15 strata using a fixed 
effects model inverse-variance method. We applied the genomic control equivalent to the per-SNP standard 
error in each stratum, controlling for the respective genomic inflation factor  (Supplementary Table 14).  
To replicate the primary SNPs per identified signal in the discovery phase, we used the replication effect 
size and respective standard error. For the secondary and tertiary SNPs, we fitted the same exact models as 
in the discovery phase, per data set.  We then performed fixed effects meta-analysis to estimate an effect size 
that corresponds to the same logistic model. In the case that a SNP was not present in the replication set, we 
replaced it with a perfectly tagging SNP, i.e. a SNP that had r
2
 and D’ equal to 1. If a perfectly tagging SNP 
was not available, we selected a SNP that had equivalent MAF and the highest possible r
2
 and D’. 
Estimation of r
2
 and D’ for this objective were based on the ImmunoChip control samples. 
 
Joint analysis (discovery and replication sets). 
The discovery and replication phase effect sizes and respective standards errors were meta-analysed under 
a fixed effects model. A SNP was considered replicated when all three of the following criteria were met: 1) 
20 
replication p-value <5.0 x 10
-2
, 2) joint p-value <5 x 10
-8
, and 3) the joint p-value was more statistically 
significant than the discovery p-value. SNPs that reached a p-value of <1 x 10
-6 
but did not pass the genome-
wide threshold, were coined suggested if the above criteria 1) and 3) were met. 
 
Fine-mapping of association signals. 
To fine-map signals of association we used a combination of imputation and Bayesian methodology.
23
  
Around each of the 97 associated SNPs, 2Mb were isolated in the discovery and replication phase UK data 
as well as the European samples from the Phase 1 1000G.
28
  Forming the single largest cohort, only UK 
samples were considered to minimize the effects of differential imputation quality between populations of 
different ancestry.  In addition to the previous quality control, SNPs with failed alignment or a difference in 
MAF >10% between the typed cohorts and the 1000G samples, MAF < 1%, or HWE p-value <1.0 x 10
-4
 
were removed.   
Imputation was performed separately for the UK discovery and replication cohorts on each 2Mb region 
using the default settings of IMPUTEv2.
43,44
 Missing genotypes in the genotyped SNPs were not imputed, 
and any imputed SNP that failed the HWE and MAF threshold was subsequently removed. We carried out 
frequentist and Bayesian association tests on all SNPs in each cohort separately, assuming additivity, using 
the default settings of SNPTESTv2.
45
  Frequentist fixed-effect meta-analysis was carried out using the 
software META.
46
 Bayesian meta-analysis was carried out using an independence prior (near-identical 
results were obtained using a fixed-effect Bayesian meta-analysis). 
To identify regions where reliable fine-mapping could be achieved, we used the information score (INFO, 
obtained from IMPUTEv2) as identified from the 1000G samples.  Specifically, we measured the fraction of 
variants with both r
2
 > 0.5 and r
2
 > 0.8 to the primary associated variant, having greater than 50% and 80% 
INFO scores respectively.  Regions where any SNP with r
2
 > 0.5 had INFO < 50% were excluded.  We also 
excluded regions where the top hit from imputation had an INFO score less than 80%.  Regions were 
considered to be fine-mapped with high quality when all variants with r
2
 > 0.8 had at least 80% INFO.  
Within these regions, we excluded variants where the inferred direction of association was opposite in the 
UK discovery and replication cohorts.   
To measure the posterior probability that any single variant drives association, we calculated the Bayes 
Factor.  Under the assumption that there is a single causal variant in the region, this is proportional to the 
probability that the variant drives the association.
23
  We identified the smallest set of variants that contained 
90% and 50% of the posterior probability.  We called a region successfully and consistently fine-mapped if 
there were at most five variants in the 50% confidence interval and the top SNP from the frequentist analysis 
lived in the 90% confidence interval.  For these regions, we annotated variants with information about 
evolutionary conservation, predicted coding consequence, regulation, published associations to expression 
21 
or DNase I hypersensitive sites using ANNOVAR,
47
 VEP,
24
 and the eQTL browser, a recent immune cell 
expression study
20
, and other literature. 
 
 
Gene Ontology. 
To determine the GO processes for which our associated variants were involved, we used MetaCore from 
Thomson Reuters.  We annotated the processes for the unique genes within 50Kb of the variants. 
Cross disease comparison. 
In order to explore the potential overlap with variants identified across other autoimmune diseases, we 
calculated the percentage overlap of reported variants found in other ImmunoChip reports to our 
ImmunoChip results. The top variants reported as either novel or previously known in other ImmunoChip 
reports were compared with the 110 variants representing both our novel and previous discoveries in 
multiple sclerosis. In order for a signal to be considered as overlapping, we required an r
2
 ≥ 0.8 using the 
Pairwise LD function of the SNAP tool in European samples.
31
 
Secondary analyses. 
We performed a severity based analysis of MSSS in cases only from the discovery phase (Supplementary 
Fig. 99).  In addition, a transmission disequilibrium test was done in 633 trios to test for transmission of the 
97 identified risk alleles (Supplementary Fig. 100). Details are given in the Supplementary Note. 
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